Lucía López‐Corral

5.7k total citations
91 papers, 2.2k citations indexed

About

Lucía López‐Corral is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Lucía López‐Corral has authored 91 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Hematology, 26 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in Lucía López‐Corral's work include Hematopoietic Stem Cell Transplantation (38 papers), Multiple Myeloma Research and Treatments (25 papers) and Acute Myeloid Leukemia Research (14 papers). Lucía López‐Corral is often cited by papers focused on Hematopoietic Stem Cell Transplantation (38 papers), Multiple Myeloma Research and Treatments (25 papers) and Acute Myeloid Leukemia Research (14 papers). Lucía López‐Corral collaborates with scholars based in Spain, United States and Italy. Lucía López‐Corral's co-authors include Jesús F. San Miguel, María‐Victoria Mateos, Norma C. Gutiérrez, Ramón García‐Sánz, Bruno Paiva, Dolores Caballero, Joan Bladé, Albert Oriol, Juan José Lahuerta and Pilar Giraldo and has published in prestigious journals such as New England Journal of Medicine, Blood and The Lancet Oncology.

In The Last Decade

Lucía López‐Corral

79 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lucía López‐Corral Spain	28	1.6k	934	699	347	289	91	2.2k
Simrit Parmar United States	27	1.6k 1.0×	1.3k 1.4×	1.0k 1.5×	466 1.3×	963 3.3×	167	2.9k
Paul Shaughnessy United States	20	1.3k 0.8×	274 0.3×	508 0.7×	269 0.8×	494 1.7×	85	1.8k
Dennis Cooper United States	27	951 0.6×	461 0.5×	1.1k 1.6×	256 0.7×	466 1.6×	112	2.8k
Martin Wermke Germany	25	2.2k 1.4×	1.2k 1.3×	1.2k 1.7×	885 2.6×	517 1.8×	152	3.7k
Elizabeth O. Hexner United States	34	1.8k 1.1×	1.1k 1.2×	1.1k 1.6×	960 2.8×	1.6k 5.7×	154	4.0k
Siddhartha Ganguly United States	21	617 0.4×	618 0.7×	784 1.1×	218 0.6×	209 0.7×	138	1.6k
Luke Coyle Australia	18	632 0.4×	376 0.4×	351 0.5×	233 0.7×	494 1.7×	46	1.5k
Michael Doubek Czechia	23	702 0.4×	612 0.7×	519 0.7×	984 2.8×	510 1.8×	169	2.3k
Yanming Zhang United States	23	494 0.3×	932 1.0×	571 0.8×	208 0.6×	179 0.6×	148	2.0k
Nigel Westwood United Kingdom	21	913 0.6×	767 0.8×	480 0.7×	862 2.5×	349 1.2×	68	2.2k

Countries citing papers authored by Lucía López‐Corral

Since Specialization

Citations

This map shows the geographic impact of Lucía López‐Corral's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucía López‐Corral with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucía López‐Corral more than expected).

Fields of papers citing papers by Lucía López‐Corral

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucía López‐Corral. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucía López‐Corral. The network helps show where Lucía López‐Corral may publish in the future.

Co-authorship network of co-authors of Lucía López‐Corral

This figure shows the co-authorship network connecting the top 25 collaborators of Lucía López‐Corral. A scholar is included among the top collaborators of Lucía López‐Corral based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucía López‐Corral. Lucía López‐Corral is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Camacho-Arteaga, Lina, Gloria Iacoboni, Mi Kwon, et al.. (2025). Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma. JAMA Network Open. 8(2). e2461683–e2461683.

López‐Corral, Lucía, et al.. (2025). Impact of the kinetics of circulating anti‐BCMA CAR‐T cells and normal lymphocytes on the outcome of MM patients. HemaSphere. 9(12). e70277–e70277.

Sanz, Jaime, Clémence Mediavilla, Lucía López‐Corral, et al.. (2025). MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: Results from the ARES phase III trial. Blood. 146(Supplement 1). 817–817.

Nagler, Arnon, Myriam Labopin, Didier Blaise, et al.. (2024). Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. 59(11). 1552–1562. 5 indexed citations

Hidalgo, Cristina, et al.. (2023). Enfermedad injerto contra receptor crónica: revisión sistemática de la afectación articular y fascial. Reumatología Clínica. 19(5). 235–243.

López‐Corral, Lucía, et al.. (2023). Neurodevelopment and early pharmacological interventions in Fragile X Syndrome. Frontiers in Neuroscience. 17. 1213410–1213410. 8 indexed citations

Rejeski, Kai, Yucai Wang, Omar Albanyan, et al.. (2023). The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. American Journal of Hematology. 98(11). 1699–1710. 17 indexed citations

Zabaleta, Aintzane, Noemí Puig, José J. Pérez, et al.. (2023). Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE). Blood. 142(Supplement 1). 94–94. 4 indexed citations

Rodríguez‐Arbolí, Eduardo, Catherine J. Lee, Teresa Caballero‐Velázquez, et al.. (2023). Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials. Clinical Cancer Research. 29(20). 4057–4067. 3 indexed citations

10.

López‐Corral, Lucía, Guillermo Martı́n, Francisco J. Márquez‐Malaver, et al.. (2021). Treatment of steroid‐refractory chronic graft‐versus‐host disease with imatinib: Real‐life experience of the Spanish group of hematopoietic transplantation (GETH). Clinical Transplantation. 35(5). e14255–e14255. 4 indexed citations

11.

Iacoboni, Gloria, Kai Rejeski, Annalisa Chiappella, et al.. (2021). Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. Blood. 138(Supplement 1). 2827–2827. 7 indexed citations

12.

Carrillo‐Cruz, Estrella, José R. García‐Lozano, Francisco J. Márquez‐Malaver, et al.. (2019). Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. Clinical Cancer Research. 25(15). 4616–4623. 7 indexed citations

13.

Pérez-Simón, Josè Antonio, Mats Remberger, Teresa Caballero‐Velázquez, et al.. (2018). Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. Medical Oncology. 35(6). 79–79. 12 indexed citations

14.

Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2016). Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. The Lancet Oncology. 17(8). 1127–1136. 107 indexed citations

15.

Caballero‐Velázquez, Teresa, Isabel Montero, Fermín Sánchez‐Guijo, et al.. (2016). Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. Clinical Cancer Research. 22(23). 5673–5681. 36 indexed citations

16.

Labopin, Myriam, Didier Blaise, G. Socié, et al.. (2015). The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 100(5). 683–689. 28 indexed citations

17.

Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2013). Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 369(5). 438–447. 348 indexed citations

18.

Barba, Pere, Rodrigo Martino, Josè Antonio Pérez-Simón, et al.. (2013). Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 20(1). 66–72. 32 indexed citations

19.

López‐Corral, Lucía, et al.. (2012). Efecto de injerto contra tumor. 13(3). 89–93. 1 indexed citations

20.

López‐Corral, Lucía, Norma C. Gutiérrez, María‐Belén Vídriales, et al.. (2011). The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells. Clinical Cancer Research. 17(7). 1692–1700. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact